Abstract
The attempts to increase novel drug productivity through creative discovery technologies have fallen short of producing the satisfactory results. For these reasons, evolved from the concept of drug repositioning, “privileged structure”-guided scaffold re-evolution/refining is a primary strategy to identify structurally novel chemotypes by modifying the central core structure and the side-chain of the existing active compounds, or to exploit undescribed bioactivites by making full use of readily derivatized motifs with well-established synthetic protocols. Herein, we review the basic tricks of exploiting privileged structures for scaffold re-evolution/refining. The power of this strategy is exemplified in the discovery of other new therapeutic applications by refining privileged structures in anti-viral agents.
Keywords: Drug design, drug repositioning, privileged structure, scaffold re-evolution, scaffold refining.
Combinatorial Chemistry & High Throughput Screening
Title:"Old Friends in New Guise": Exploiting Privileged Structures for Scaffold Re-Evolution/Refining
Volume: 17 Issue: 6
Author(s): Yu'ning Song, Wenmin Chen, Dongwei Kang, Qingzhu Zhang, Peng Zhan and Xinyong Liu
Affiliation:
Keywords: Drug design, drug repositioning, privileged structure, scaffold re-evolution, scaffold refining.
Abstract: The attempts to increase novel drug productivity through creative discovery technologies have fallen short of producing the satisfactory results. For these reasons, evolved from the concept of drug repositioning, “privileged structure”-guided scaffold re-evolution/refining is a primary strategy to identify structurally novel chemotypes by modifying the central core structure and the side-chain of the existing active compounds, or to exploit undescribed bioactivites by making full use of readily derivatized motifs with well-established synthetic protocols. Herein, we review the basic tricks of exploiting privileged structures for scaffold re-evolution/refining. The power of this strategy is exemplified in the discovery of other new therapeutic applications by refining privileged structures in anti-viral agents.
Export Options
About this article
Cite this article as:
Song Yu'ning, Chen Wenmin, Kang Dongwei, Zhang Qingzhu, Zhan Peng and Liu Xinyong, "Old Friends in New Guise": Exploiting Privileged Structures for Scaffold Re-Evolution/Refining, Combinatorial Chemistry & High Throughput Screening 2014; 17 (6) . https://dx.doi.org/10.2174/1386207317666140122101631
DOI https://dx.doi.org/10.2174/1386207317666140122101631 |
Print ISSN 1386-2073 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5402 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
New Mechanistic Insight on the PIM-1 Kinase Inhibitor AZD1208 Using Multidrug Resistant Human Erythroleukemia Cell Lines and Molecular Docking Simulations
Current Topics in Medicinal Chemistry The Aryl Hydrocarbon Receptor Nuclear Translocator (ARNT) Family of Proteins: Transcriptional Modifiers with Multi-Functional Protein Interfaces
Current Molecular Medicine Chidamide Inhibits Cell Proliferation via the PI3K/AKT Pathway in K562 Cells Based on Network Pharmacology and Experimental Validation
Current Pharmaceutical Design Oncogenic MicroRNAs in the Genesis of Leukemia and Lymphoma
Current Pharmaceutical Design The Effects of All-Trans-Retinoic Acid on Cell Cycle and Alkaline Phosphatase Activity in Pancreatic Cancer Cells
Medicinal Chemistry Tyrosine Kinases as Therapeutic Targets in BCR-ABL Negative Chronic Myeloproliferative Disorders
Current Drug Targets Cell Penetrating Peptides as a Therapeutic Strategy in Chronic Lymphocytic Leukemia
Protein & Peptide Letters Editorial [Hot Topic: Beyond Chemotherapy: Future Directions in Lymphoma Treatment (Guest Editor: Thomas Decker)]
Current Drug Targets Contrast Enhanced Ultrasonography for Focal Liver Lesions Characterization: Clinical Perspective
Current Medical Imaging Bcl-2 Family Proteins as Therapeutic Targets
Current Pharmaceutical Design Non-Melanoma Skin Cancer – Overview
Current Cancer Therapy Reviews Imaging Requirements for Personalized Medicine: The Oncologists Point of View
Current Pharmaceutical Design Treatment of Acute Leukaemias with Monoclonal Antibodies: Current Status and Future Prospects
Cardiovascular & Hematological Agents in Medicinal Chemistry Targeting Phosphatidylserine in Anti-Cancer Therapy
Current Pharmaceutical Design Clinical Application of Percutaneous Puncture Biopsy Guided by Fused and 3D-reconstructed PET/CT Images
Current Medical Imaging Targeting MDM4 as a Novel Therapeutic Approach for Hematologic Malignancies
Current Cancer Drug Targets Double-Edged Effects of Arsenic Compounds: Anticancer and Carcinogenic Effects
Current Drug Metabolism Assessment of Bishosphonate Activity In Vitro
Current Pharmaceutical Design Polymorphisms of Human N-Acetyltransferases and Cancer Risk
Current Drug Metabolism Bioactive Polyphenols from Grapes and Wine Emphasized with Resveratrol
Current Pharmaceutical Design